Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling

Endocrinology

Volumn 155, Issue 4, 2014, Pages 1207-1221

  Malaguarnera, Roberta ^a   Sacco, Antonella ^a   Morcavallo, Alaide ^a   Squatrito, Sebastiano ^b   Migliaccio, Antimo ^c   Morrione, Andrea ^d   Maggiolini, Marcello ^e   Belfiore, Antonino ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CRE RECOMBINASE; CREB REGULATED TRANSCRIPTION COACTIVATOR 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; S6 KINASE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTIANDROGEN THERAPY; CANCER CELL; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MEMBRANE DAMAGE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ANDROGENS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CREB-BINDING PROTEIN; DENSITOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEK293 CELLS; HUMANS; MALE; METFORMIN; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84897879220     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1925     Document Type: Review

References (44)

1. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002;108:465-474. (Pubitemid 34260872)
2. Castoria G, Migliaccio A, D'Amato L, et al. Integrating signals between cAMP and MAPK pathways in breast cancer. Front Biosci. 2008;13:1318-1327. (Pubitemid 351606113)
3. Michels G, Hoppe UC. Rapid actions of androgens. Front Neuroendocrinol. 2008;29:182-198.
4. De Bellis A, Ghiandi P, Comerci A, et al. Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-α in human hyperplastic prostate tissue: expression and cellular localization. J Clin Endocrinol Metab. 1996;81:4148-4154. (Pubitemid 26380431)
5. Pandini G, Mineo R, Frasca F, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res. 2005;65:1849-1857. (Pubitemid 40478613)
6. Genua M, Pandini G, Sisci D, et al. Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells. Cancer Res. 2009;69:7270-7277.
7. He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137:635-646.
8. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48:R31-43.
9. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci. 2013;34:126-135.
10. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576-3586. (Pubitemid 351793803)
11. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010;9:1092-1099.
12. Colquhoun AJ, Venier NA, Vandersluis AD, et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012;15:346-352.
13. Kalender A, Selvaraj A, Kim SY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11:390-401.
14. Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71:4366-4372.
15. Malki A, Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res. 2011;19:275-285.
16. Kim HG, Hien TT, Han EH, et al. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2011;162:1096-1108.
17. Hwang YP, Jeong HG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Cα-dependent pathway: phorbol-12-myristate-13-acetate- induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol. 2010;160:1195-1211.
18. Kumar N, Dey CS. Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells. Br J Pharmacol. 2002;137:329-336.
19. Migliaccio A, Varricchio L, De Falco A, et al. Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene. 2007;26:6619-6629. (Pubitemid 47573684)
20. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem. 2002;277:39684-39695. (Pubitemid 35190951)
21. Sieg DJ, Ili D, Jones KC, Damsky CH, Hunter T, Schlaepfer DD. Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK- cell migration. EMBO J. 1998;17:5933-5947. (Pubitemid 28474788)
22. Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R, Belfiore A. Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology. 2012;153:2152-2163.
23. Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev. 2010;3:374-391.
24. Ellisen LW, Ramsayer KD, Johannessen CM, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002;10:995-1005. (Pubitemid 35453821)
25. Guo Z, Dai B, Jiang T, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 2006;10:309-319. (Pubitemid 44512189)
26. Conkright MD, Canettieri G, Screaton R, et al. TORCs: transducers of regulated CREB activity. Mol Cell. 2003;12:413-423. (Pubitemid 37238928)
27. Screaton RA, Conkright MD, Katoh Y, et al. The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell. 2004;119:61-74. (Pubitemid 39349320)
28. Dentin R, Liu Y, Koo SH, et al. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature. 2007;449:366-369. (Pubitemid 47443476)
29. Horike N, Sakoda H, Kushiyama A, et al. AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3β and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver. Journal Biol Chem. 2008;283:33902-33910.
30. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577-590. (Pubitemid 37506046)
31. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214-226. (Pubitemid 351626684)
32. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008;22:239-251.
33. Werner H, Shalita-Chesner M, Abramovitch S, Idelman G, Shaharabani-Gargir L, Glaser T. Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer. Mol Genet Metab. 2000;71:315-320.
34. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998;58:2720-2723. (Pubitemid 28311897)
35. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648-657. (Pubitemid 34993700)
36. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002;10:151-162. (Pubitemid 34876569)
37. Huang J, Manning BD. Acomplex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009;37:217-222.
38. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2013;63:709-716.
39. Frid A, Sterner GN, Löndahl M, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33:1291-1293.
40. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3:607-614. (Pubitemid 30410251)
41. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24:49-57. (Pubitemid 24058005)
42. Carvalho C, Correia S, Santos MS, Seiça R, Oliveira CR, Moreira PI. Metformin promotes isolated rat liver mitochondria impairment. Mol Cell Biochem. 2008;308:75-83. (Pubitemid 351167847)
43. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507-7511.
44. Margel D, Urbach DR, Lipscombe LL, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 2013;31:3069-3075.